Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus
Open Access
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 151, 50-54
Abstract
No abstract availableKeywords
Funding Information
- JPM-MCS (B.09)
This publication has 12 references indexed in Scilit:
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse modelAntiviral Research, 2014
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus PolymerasePLOS ONE, 2013
- T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell CultureAntimicrobial Agents and Chemotherapy, 2011
- T-705 (favipiravir) activity against lethal H5N1 influenza A virusesProceedings of the National Academy of Sciences, 2009
- Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cellsJournal of Antimicrobial Chemotherapy, 2009
- Mechanism of Action of T-705 against Influenza VirusAntimicrobial Agents and Chemotherapy, 2005
- A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic FeverThe Journal of Infectious Diseases, 1998